Benutzerspezifische Werkzeuge

Lungenkarzinom

NSCLC: Boehringer-Ingelheim 1336-0011

An open label phase Ib dose finding study of BI 836880 in combination with BI 754091 to characterize safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy in check point inhibitor naive patient with locally advanced or metastatic nonsquamous Non-Small Cell Lung ...Mehr…

NSCLC: Find

A phase II trial to evaluate efficacy and safety of erdafitinib in patients with advanced NSCLC harboring FGFR genetic alterations after relapse of standard therapy.Mehr…